NextCell Pharma AB

65G

Company Profile

  • Business description

    NextCell Pharma AB is a Swedish clinical-stage biotechnology company developing mesenchymal stromal cell (MSC)-based therapies for autoimmune and inflammatory diseases, with a primary focus on Type 1 Diabetes. Its key product candidate, ProTrans, is designed to preserve insulin-producing capacity in Type 1 Diabetes patients, while the company also operates Cellaviva, Scandinavia's private stem-cell bank, and QVance, which provides analytical and quality-control services for therapy medicinal products. It's operations are organized into three business areas: ProTrans (cell therapy development), Cellaviva (stem-cell banking), and QVance (ATMP analytical services). The company's activities are concentrated in Sweden and the Nordic region.

  • Contact

    Karolinska Institutet Science Park
    Halsovagen 7
    Huddinge14157
    SWE

    T: +46 87355595

    https://www.nextcellpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    24

Stocks News & Analysis

stocks

Reassuring organic growth for undervalued ASX share

Efficiency gains are starting to make their mark.
stocks

Big IPOs are enticing but are they good investments?

Historically, buzzy debuts have been painful for buyers.
stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,692.80143.80-1.63%
CAC 407,927.75152.99-1.89%
DAX 4024,802.78661.03-2.60%
Dow JONES (US)48,147.33949.73-1.93%
FTSE 10010,346.34106.34-1.02%
HKSE22,410.80430.82-1.89%
NASDAQ22,617.731,261.47-5.28%
Nikkei 22556,436.653,007.56-5.06%
NZX 50 Index14,107.41139.84-0.98%
S&P 5006,910.39265.44-3.70%
S&P/ASX 2008,592.60137.80-1.58%
SSE Composite Index3,533.7943.82-1.22%

Market Movers